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Abstract Obstructive Sleep Apnea (OSA), characterized by airflow cessation (apnea) or 
reduction (hypopnea) due to repeated pharyngeal obstructions during sleep, causes 
frequent disruption of sleep and hypoxic events. The condition is linked to many adverse 
health related consequences, such as neurocognitive and cardiovascular disorders, and 
metabolic syndrome. OSA is a chronic condition requiring long-term treatment, so 
treatment using continuous positive airway pressure (CPAP) has become the gold standard 
in cases of moderate or severe OSA. However, its effectiveness is influenced by patients’ 
adherence. Surgery for OSA or treatment with oral appliances can be successful in selected 
patients, but for the majority, lifestyle changes such as exercise and dietary control may 
prove useful. However, exercise training remains under-utilized by many clinicians as an 
alternative treatment for OSA. Other interventions such as oral appliance (OA), upper way 
stimulation, and oropharyngeal exercises are used in OSA. Because the benefit of all these 
techniques is heterogeneous, the major challenge is to associate specific OSA therapies 
with the maximum efficacy and the best patient compliance. 
Keywords  OSA, oral appliance, upper way stimulation, oropharyngeal exercises, pulmonary 
rehabilitation 
Highlights ✓ Even though the role of OA is similar to that of CPAP in clinical practice, clinicians may 
not achieve the abolition of all obstructive events during sleep by means of OA. 
✓ There is currently an alternative therapy to CPAP or OA for subjects with mild to moderate 
OSA, consisting in the use of upper airway stimulation devices.    
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Introduction 
Obstructive sleep apnea is characterized by airflow 
cessation (apnea) or reduction (hypopnea) due to repeated 
pharyngeal obstructions during sleep, causing frequent 
disruption of sleep and hypoxic events. The 
pathophysiology of OSA varies and includes different 
underlying mechanisms, such as the effectiveness of the 
upper airway dilator muscles (genioglossus), the upper 
airway anatomy, the arousal threshold of the individual, 
and the inherent stability of the respiratory control system 
(1). It is well-know that obesity is the most significant risk 
factor, with other factors such as smoking, alcohol abuse, 
chronic nasal congestion, male gender, age, and the use of 
sedative medications playing a significant role in OSA 
development (2, 3). In addition, OSA is linked to many 
adverse health-related consequences, such as 
neurocognitive and cardiovascular disorders, and 
metabolic syndrome (4, 5, 6). OSA has become a chronic 
condition which requires long-term treatment, so treatment 
using continuous positive airway pressure (CPAP) has 
become the gold standard in cases of moderate or severe 
OSA, but its effectiveness is influenced by patients’ 
adherence. Surgery for OSA or treatment with oral 
appliances can be successful in selected patients (4), but for 
the majority, lifestyle changes such as exercise and dietary 
control may also prove useful. However, exercise training 
remains under-utilized by many clinicians as the 
alternative treatment for OSA (7). Other interventions such 
as oral appliance (OA), upper way stimulation, and 
oropharyngeal exercises are used in OSA.  
Discussion 
Prevalence 
OSA has been recognized as a very common pathology 
in recent years, but it still remains undiagnosed and 
untreated in many cases. Apnea-hypopnea index (AHI) 
quantifies both sleep apnea severity and the number of 
apneal or hypopneal obstructive events per hour of sleep. 
The prevalence of OSA was found to be 24% in men and 
9% in women aged 30-60 years, thus defining OSA as an 
AHI greater than 5 events/hour in the Wisconsin Sleep 
Cohort in the United States of America. The values of 
prevalence worldwide do not vary significantly, thus 
confirming that OSA is as common in the developing 
world as in the occidental society (8). In Europe, the 
prevalence may be even greater, taking into account that 
modern diagnostic techniques are used. For example, in a 
Swiss study including over 2,000 subjects with the 
diagnosis of moderate-severe OSA, the prevalence was 
23.4% in females and 49% in males (9). 
Risk Factors 
The highest risk factor for OSA is obesity, especially 
central adiposity. According to the worsening pandemic 
obesity worldwide, the prevalence of OSA is yet 
increasing. Moreover, obesity may contribute to the 
development of OSA by affecting the upper airway 
mechanisms (2). The deposition of fat in the 
parapharyngeal region can reduce the caliber and promote 
collapsibility by modifying the shape of the upper airway. 
Obesity is also responsible for reducing the lung volumes 
and increasing airflow resistance (10). In the pathogenesis 
of obesity, a key role is represented by the interaction 
between OSA and obesity, in part because excessive 
daytime sleepiness and other symptoms of OSA may 
accelerate weight gain due to reduced physical activity and 
energy expenditure. Weight loss is a key measure of 
therapy for overweight or obese patients with OSA, as it 
may confer a positive impact on other diseases such as 
cardiovascular disorders and type 2 diabetes and it may 
reduce the severity of OSA (8, 11). 
There is an age-related increase in the prevalence of 
OSA. Some mechanisms include changes in the anatomic 
parapharyngeal structures, parapharyngeal fat deposition, 
and lengthening of the soft palate (12). It is also well 
acknowledged that there is a 2 to 3-fold higher prevalence 
of OSA in men compared to women (8). Men present 
themselves more often for the clinical assessment for OSA 
because they have typical symptoms of OSA (loud snoring, 
witnessed apneas, and excessive daytime sleepiness). This 
fact is responsible for the underdiagnosed OSA in women, 
with women more likely presenting with atypical 
symptoms such as poor energy levels and fatigue (13). 
In addition, multiple craniofacial features related to 
pharyngeal soft tissue or skeletal morphology may 
predispose to upper airway collapse. Hyoid position, 
mandibular size, and maxillary height have been associated 
with an increased risk for OSA. Decreased velopharyngeal 
area and tonsillar hypertrophy are soft tissue features that 
have been associated with increased upper airway 
collapsibility (1). 
Smoking is another factor implicated in the 
development of OSA. The data are controversial, as the 
effect of nicotine decreases the upper airway resistance 
with a consequent reduction in the risk of OSA, whereas in 
case of withdrawal, this resistance would become more 
important and would cause a greater risk of OSA. Smoking 
is a well-acknowledged risk factor for respiratory diseases, 
various neoplasia, and metabolic disorders. Various 
compounds in cigarette smoke, such as volatile organic 
compounds, heavy metals, and nicotine are responsible for 
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the increased oxidative stress and systemic inflammation, 
with an important role in the occurrence of lipid and 
glucose metabolic dysfunction and endothelial injury, 
resulting in the development of cardiovascular, cognitive, 
and metabolic disorders (14, 15). 
Diagnosis 
Recognizing and treating OSA is very important in 
clinical practice. The first step in the diagnosis is a clinical 
evaluation, which involves a sleep history and a physical 
examination of the respiratory, cardiovascular, and 
neurologic systems. The examiner should note symptoms 
such as snoring, witnessed apneas, nocturnal choking or 
gasping, and restlessness and excessive sleepiness. The 
differential diagnosis is made through the general 
evaluation in order to select the appropriate test(s) and to 
recognize the associated medical conditions such as 
obesity, hypertension, stroke, and congestive heart failure. 
In the diagnosis of OSA, nocturnal polysomnography is the 
gold standard, but in cases of high suspicion of OSA, 
nocturnal cardiorespiratory polygraphy is edifying. In the 
third edition of the International Classification of Sleep 
Disorders (ICSD-3), OSA is defined as a respiratory 
disturbance index (RDI) ≥ 5 events/hour of sleep in 
patients who associate typical symptoms of OSA (daytime 
sleepiness, fatigue or insomnia, unrefreshing sleep, loud 
snoring, witnessed apneas, awakening with a gasping or 
choking sensation), or an RDI ≥ 15 events/hour of sleep 
(even in the absence of symptoms) (16).  
Comorbidities 
A high prevalence of comorbidities in seen in OSA 
patients (17). There are specific patterns, with men more 
often affected by diabetes and ischemic hearts disease and 
women by hypertension and depression (18, 19). Also, 
OSA is responsible for the development of cardiovascular 
and cerebrovascular diseases through high sympathetic 
nervous activity, oxidative stress, systemic inflammation, 
intermittent hypoxia, systemic hypertension, endothelial 
cell dysfunction, and accelerated atherosclerosis. Systemic 
hypertension is the most studied cardiovascular 
comorbidity in OSA. Respiratory events such as apneas or 
hypopneas during sleep are followed by hypertensive 
peaks, so that a variability of blood pressure may occur. 
Another aspect in these patients is resistant hypertension or 
incomplete blood pressure control on maximum drug 
therapy (20). In patients with OSA, atrial fibrillation is very 
frequent, with CPAP therapy having a protective role (21). 
Another pathology with a high prevalence in OSA patients 
with central obesity is metabolic syndrome (MetS), 
responsible for increasing cardiovascular risk. Recent 
studies have also shown that OSA is part of the MetS. The 
intermittent hypoxia and the sleep loss or fragmentation are 
involved in the pathogenesis of insulin resistance (17). In 
these conditions, OSA treatment with sufficient adherence 
(at least 4 hours/night) is required besides the 
implementation of lifestyle interventions and weight loss 
programs (22).  
The association between OSA and chronic obstructive 
pulmonary disease (COPD), known as “overlap syndrome” 
from the early studies (23), has a prevalence of 1.0 to 3.6% 
in the general population, 8-56% in OSA patients, and 3-
66% in COPD patients (24). In COPD patients who have 
consulted clinicians for pulmonary rehabilitation, a severe 
form of OSA has been diagnosed in 45% of the cases, with 
these patients having poor sleep quality and 
hypoventilation episodes during sleep (17, 25). Moreover, 
overlapping patients have higher rates of mortality 
compared to OSA patients, and in this direction there is a 
protective effect of CPAP treatment (26). These data 
suggest that a low body mass index (BMI) in patients with 
COPD protects against OSA, but the upper airway and the 
systemic inflammation are responsible for increasing the 
prevalence of OSA in COPD patients (27).  
Asthma and OSA are often associated, so asthmatic 
patients often report symptoms such as daytime sleepiness, 
poor asthma control, and poor quality of life.  In patients 
with difficult-to-treat asthma, the prevalence of OSA is 
about 49%. Patients with severe asthma show poor sleep 
quality and excessive daytime sleepiness. Often, asthmatic 
patients present hypopneas. It appears that both asthma and 
OSA play a synergistic role in the upper airway 
inflammation, in part because the upper airways seem to be 
smaller in patients with asthma and OSA (17). 
Therapeutic Attitudes in OSA 
In the last two decades, advances in sleep medicine and 
the availability of improved diagnostic tools have led to a 
better recognition and treatment of the disease. The 
management of patients with OSA requires a 
multidisciplinary approach, and many treatment options 
are currently available in order to eliminate the nocturnal 
apnea events and the intermittent hypoxia. Positive airway 
pressure (PAP), available since the beginning of the 1980s, 
provides the most effective and commonly used treatment. 
PAP devices function as a pneumatic support that 
maintains upper airway patency by increasing the upper 
airway pressure above a ‘critical’ value (the pressure value 
under which the airways collapse). The device is applied to 
the patient through a nasal or oronasal mask, overnight or 
during sleep hours at a set positive pressure. This pressure 
can vary according to the severity of OSA, so higher 
Corina Eugenia Budin et al. 
 184 
pressures are needed in order to make nocturnal apneas 
disappear. PAP therapy is indicated in patients with an AHI 
greater than 15 events/hour of sleep, independently from 
the presence of comorbidities and severity of symptoms. If 
the AHI is above 5 and below 15, PAP is indicated in the 
presence of comorbidities such as hypertension, coronary 
artery disease, or previous cerebrovascular accidents, or in 
the presence of other symptoms (i.e., sleepiness, impaired 
cognition, mood disorders) (28, 29). Alternative options 
include weight control, mandibular advancement devices, 
oral appliance, upper airway stimulation, oropharyngeal 
exercises, and a number of upper airway surgical 
approaches.  
Lifestyle Intervention 
As previously shown, obesity is an important risk factor 
for OSA, and over 70% of patients with OSA suffer from 
obesity. A strict correlation has recently been established 
between the body mass index (BMI) and AHI. Weight loss 
is therefore a main goal in the management of OSA and all 
patients should be encouraged to control their weight (30).  
The term “Mediterranean diet” refers to many common 
features including the abundant use of olive oil as the main 
culinary source of fat, plentiful consumption of plant-based 
foods (e.g. nuts, vegetables, fruits, cereals, grains and 
vegetables), consumption of fresh and varied fruits, 
frequent consumption of fish and other seafood, moderate 
wine consumption with meals, limited meat (mainly 
poultry) or processed meat intake, and low-to-moderate 
consumption of processed products (31). Besides this, the 
Mediterranean diet is characterized by abundant plant 
foods with antioxidant molecules which have an anti-
inflammatory effect. Longer beneficial effects of a 
moderate-carbohydrate (40%), high-fat (40%) calorie-
restricted Mediterranean diet on weight and waist 
circumference have been demonstrated among individuals 
with metabolic syndrome or more cardiovascular risk 
factors. Therefore, a Mediterranean diet seems a promising 
approach to reduce mechanical loads and thus improve 
OSA severity, compared to a low-fat, calorie-restricted diet 
(32, 33). 
In a study comparing the Mediterranean diet with a 
low-carb diet, patients in the Mediterranean diet group had 
a greater improvement in AHI after 6 months, mainly due 
to an important reduction of the waist circumference, 
improved upper airway neuromuscular control, and upper 
airway muscular capacity (34). 
While dietary-induced weight loss is effective in the 
treatment of OSA, OSA influences weight loss through 
sleep fragmentation and poor sleep quality, so these 
mechanisms could have implications for therapeutic 
approaches. Borel et al. studied this assumption in a group 
of males with visceral adiposity who underwent a weight 
loss intervention that included nutritional counselling and 
moderate physical activity promotion. At one-year follow-
up, males with OSA had smaller reductions in waist 
circumference, in total fat mass and triglycerides, and 
attenuated improvement in high-density lipoprotein 
cholesterol compared to males without OSA (35). In a 
study by Spiegel et al. (36), the variation of leptin and 
ghrelin levels were correlated with increased sympathetic 
nervous system activity or cardiac sympathovagal balance 
due to sleep loss. In addition, the subjects with sleep 
deprivation self-reported increased hunger, probably due to 
increased signaling towards reward and pleasure centers of 
the brain that enhance the hedonic perception of food, 
which would drive motivation for food seeking and 
consumption. The obvious implication of these findings is 
that inadequate sleep resulting from OSA could promote 
excessive eating, especially with high carbohydrate 
content, and impair weight loss, but there was no 
information related to diet prior to undergoing these sleep 
protocols (36, 37). 
Training Programs 
Physical activity (PA) has been recognized as a key 
determinant for good health. PA is defined as any training 
program resulting in energy expenditure. A PA plan is 
scheduled, repetitive, structured, and purposive in the sense 
that it maintains or improves one or more objectives (38). 
Moreover, several studies have demonstrated that low 
levels of PA are associated with higher incidence of OSA, 
obesity, and metabolic syndrome (39, 40). It is possible that 
patients with OSA are unable to do physical exercises due 
to excessive daytime sleepiness and fatigue (39). The 
exercises have multiple effects on OSA, such as improving 
the severity of OSA, decreasing the severity of central 
sleep apnea in patients with chronic heart failure and 
reducing the occurrence of cardiovascular diseases, 
impaired glucose tolerance, and fatigue (41). The AASM 
recommends training programs as a treatment option for 
patients with OSA, given that regular PA reduces the 
prevalence of OSA (42, 43).  
A meta-analysis by Iftikar et al. showed that exercise 
training has a significant effect on AHI that seems to be 
independent of the BMI changes. The exercises improve 
upper airway dilator functions during sleep and another one 
refers to the possibilities of including PA in the daily 
routine that seems a reorganization of parapharyngeal fat 
distribution and diminishes the arousals. Moreover, the 
improvement in sleep efficiency with exercise is similar to 
what is typically achieved with CPAP. Likewise, the 
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effects on daytime sleepiness (as measured by the Epworth 
Sleepiness Scale) with exercise training is similar to those 
seen with CPAP (44). 
Oral Appliance 
Oral appliances (OA) are the second most-used therapy 
in treating snoring and mild to moderate OSA as a primary 
therapy or as an alternative in patients who do not tolerate 
CPAP devices. It involves the application of dental splints 
in order to maintain the mandible in an advanced position 
and/or the tongue in a protruded position, in order to 
prevent upper airway obstruction during sleep. Imaging 
studies show that the lateral dimension of the 
velopharyngeal region is increased due to mandibular 
advancement resulting in an enlarged upper airway space. 
The lateral tissue movement via connections between the 
lateral walls and the ramus of the mandible leads to the 
lateral expansion of the airway space. Also, the mandibular 
advancement determines an anterior tongue movement. 
While CPAP and OA therapies are responsible for reducing 
the upper airway collapse during sleep, they differ in 
efficacy, cost and side effects. The type of OA device is 
very important in order to quantify the amount of 
mandibular advancement responsible for the decrease of 
AHI (45). The role of adjustable OA devices is to obtain 
the optimum symptom relief and achieve a significant 
reduction in the AHI for subjects with a baseline AHI >10 
events/hour of sleep (46, 47).  
Generally, the treatment effect is determined by the 
level of advancement, but clinicians must take into 
consideration the potential side effects. One study by Kato 
et al. compared 3 levels of advancement (2, 4, and 6 mm), 
concluding that improvement in overnight oximetry (25%, 
48% and 65% of patients showing improvement in 
desaturation) and in the upper airway closing pressures 
varies with the degree of advancement (48). In mild to 
moderate OSA patients, there is no significant difference 
between the levels of advancement (50% or 75%) in 
reducing AHI or the proportion of patients successfully 
treated (49). However, in patients with severe OSA, 
maximizing the level of advancement by 75% compared to 
the 50% maximum advancement is important in order to 
achieve a successful treatment (50). 
OA therapy has often been indicated in mild cases of 
OSA, and the severity of OSA decreases even more with 
OA in patients with higher baseline AHI, but there is a 
smaller probability of achieving an AHI < 5 events/hour of 
sleep. Despite the inferiority of efficacy when compared 
with CPAP, OA is preferable in patients who do not 
tolerate CPAP, being very useful in such cases. Lorenzi-
Filho demonstrated that when compared to CPAP, OA has 
the same effectiveness on symptomatology such as 
excessive daytime sleepiness, quality of life, and the 
improvement of cardiovascular biomarkers such as 
endothelial function, blood pressure, and microvascular 
reactivity (51). In obese patients, while the BMI increases, 
OA is not so efficient. OA should be considered a 
potentially complementary therapy in addition to CPAP in 
order to improve treatment outcomes. Almeida et al. 
demonstrated that patients who were compliant with CPAP 
(>4 hours/night) showed improvements in 
symptomatology (especially excessive daytime 
sleepiness), even in the nights they were not wearing it by 
using OA. Patients using OA have an option for a day off 
CPAP, resulting in less pressure on the teeth by wearing 
OA. Combination therapies are preferred in order to 
improve adherence, with a decrease of a specific treatment 
side effect or burden. In conclusion, the oral appliance is 
used specifically to decrease snoring in mild, moderate, or 
severe OSA, preferably intermittently or with CPAP as it 
is a simple and cost-effective therapy (52). 
Upper Airway Stimulation 
Unilateral and phasic upper airway stimulation (UAS) 
stimulates the hypoglossal nerve, resulting in the 
augmentation of the neural drive, through a device that acts 
via a cuff electrode connected to an implanted impulse 
generator that incorporates an effort sensor placed between 
the intercostal muscles. Only one device is currently 
approved by the Food and Drug Administration (FDA) in 
the USA. In this way, the tongue protrudes through a 
stimulation sequence that can be programmed. The UAS 
can be turned on by the patient with a programmer and it is 
used only during the sleep period and can be activated via 
a patient programmer. By combining the forward 
movement of the tongue with the mechanical coupling of 
the soft palate, clinicians can obtain an enlargement of the 
retro lingual and retro palatal airways (53). The 
Stimulation Therapy for Apnea Reduction (STAR) 
improved the oxygen desaturation index by 70% (25.4 to 
7.4 events/h), reduced AHI by 68% (29 to 9 events/h), and 
also had a beneficial effect on decreasing the arousal index. 
This device can also be used as an additional tool in 
subjects with moderate to severe OSA because it improves 
the excessive daytime sleepiness as quantified by the 
Epworth Sleepiness Scale (ESS) and increases the quality 
of life as measured by the Functional Outcomes of Sleep 
Questionnaire (FOSQ). Before proceeding to UAS, OA 
should be the first recommended procedure. These 
procedures will improve the hypoglossal nerve mapping 
and how clinicians might quantify the impact of UAS in 
anatomy. Studies have shown that UAS is not an option for 
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morbidly obese patients, but more sophisticated analyses 
(imaging and/or polysomnography) need to be done. 
Examining the role of complementary treatments in 
incomplete responders with targeted surgery, OA, weight 
loss, or medications needs to be explored (54).  
Oropharyngeal Exercises 
Considering the role of the dilator muscles of the upper 
airway in OSA, several studies have investigated the 
effects of oropharyngeal exercises on OSA severity. 
Oropharyngeal exercises (Oropharyngeal myotherapy - 
OMT) are a treatment modality used for patients with 
orofacial myofunctional disorders, with benefits on the 
orofacial structures and on the cervical muscles. OMT 
implies exercises and other strategies capable of increasing 
sensitivity, proprioception, mobility, coordination, and 
strength of orofacial structures. At the same time, OMT 
favors a good performance of respiration, mastication, 
deglutition, and speech.  Guimarães et al. demonstrated 
that oropharyngeal exercises target soft palate elevation 
and that they recruit several upper airway muscles, such as 
the tensor and the levator veli palatini, as well as the muscle 
fibers of the palatopharyngeal and palatoglossal muscle, 
tongue repositioning, and training of the mandibular 
elevation in order to avoid mouth opening during the night 
(55). One of the goals of training was to increase the tone 
of the elongated soft palate and uvula, as it is well-known 
that elongation of this structure is associated with higher 
rates of obstructive apnea, AHI, and respiratory 
disturbance index (56). The study included 31 patients with 
moderate OSA and divided them into two groups: the first 
group received placebo, and the other group received OMT 
targeting the lateral pharyngeal wall, the tongue, and the 
soft palate (55). After three months of exercise training, 
AHI was reduced by 39% and the lowest oxygen saturation 
during sleep was elevated. Another recent review 
demonstrated a 50% reduction of AHI in patients with 
OMT (57). Also, in cases of a mean baseline ESS score 
greater than 10, patients showed a significant improvement 
after OMT, with a mean reduction of six points (58). More 
recently, Ieto et al. have shown that after 3 months of 
oropharyngeal exercises, subjects showed a 36% reduction 
in snoring frequency and a 59% reduction in the overnight 
power of snoring (59). In addition, another study showed 
that oropharyngeal exercises cause various effects in the 
treatment of mild to moderate obstructive sleep apneal 
syndrome, such as: the significant reduction of the patients’ 
neck circumference, the improvement of symptoms like 
daytime sleepiness and snoring intensity, the significant 
improvement in sleep indices minimum oxygen saturation, 
SaO2 < 90 %, sleep efficiency, arousal index, and total 
sleep time N3 stage of sleep. Although it is not clear how 
OMT can influence the collapsibility of the upper airway 
during sleep, it has been speculated that OMT can 
influence the remodeling of the upper airway. The 
oropharyngeal exercises are a complex and integrated 
approach, which is why clinicians cannot quantify the 
improvement of each exercise. In addition, the exercises 
must be performed with a specific frequency (two or three 
times a day) and this may limit the clinical applicability. 
Therefore, how well patients adhere to oropharyngeal 
exercises in ‘real-world’ clinical practice is still unknown 
(60). 
Conclusions 
Over the past years, due to the increasing prevalence of 
OSA, new therapies beyond CPAP have been developed 
and are now currently available. The first treatment option 
in selected cases with mild OSA is OA, but new evidence 
also suggests that OA may be effective in selected 
moderate to severe OSA cases.  
Even though the role of OA is similar to that of CPAP 
in clinical practice, clinicians may not achieve the abolition 
of all obstructive events during sleep by means of OA. 
There is currently an alternative therapy to CPAP or OA 
for subjects with mild to moderate OSA, consisting in the 
use of upper airway stimulation devices. The principle of 
oropharyngeal exercises is repetitive muscle training, with 
specific gains in the endurance of muscles, tonicity, and 
coordination that may improve the condition of muscle 
fatigue in subjects with OSA and act on the equilibrium of 
contraction between the different muscles that involve the 
velopharyngeal, oropharyngeal, and hypo pharyngeal 
segments.  
In addition, they can decrease the volume of specific 
structures and fat in the pharyngeal-dilating muscles, thus 
also reducing the potential upper airway collapse in apneic 
subjects. However, these hypotheses have not yet been 
verified. Because the benefit of all these techniques is 
heterogeneous, the major challenge is to associate specific 
OSA therapies with maximum efficacy and optimal patient 
compliance. 
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